We would like to respond to issues raised by Balcar and Nanitsos on our study of cortical glutamatergic markers in schizophrenia (Scarr et al, 2005) . Before addressing the issue raised by Balcar and Nanitsos, we would first emphasize that their comments only focus on a small component of our paper without acknowledging that we have completed a comprehensive study of cortical glutamatergic markers in schizophrenia. Moreover, they do not mention that the data from our study strongly supports the hypothesis that the density of the kainate receptor is decreased across the dorsolateral prefrontal cortex (DLPFC) of subjects with schizophrenia and that this decrease appears to be associated with a decrease in the expression of the GluR5, but not GluR6, GluR7, KA1 or KA2, subunit of the kainate receptor. In addition, our radioligand binding data did not support the notion that the density of the Nmethyl D-aspartate (NMDA) receptor, measured using two radioligands directed at two discrete sites of the NMDA receptor, or the amino-3-hydroxyl-5-methyl-4-isoxazole (AMPA) receptor is altered in subjects with the disorder.
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Sir
We would like to respond to issues raised by Balcar and Nanitsos on our study of cortical glutamatergic markers in schizophrenia (Scarr et al, 2005) . Before addressing the issue raised by Balcar and Nanitsos, we would first emphasize that their comments only focus on a small component of our paper without acknowledging that we have completed a comprehensive study of cortical glutamatergic markers in schizophrenia. Moreover, they do not mention that the data from our study strongly supports the hypothesis that the density of the kainate receptor is decreased across the dorsolateral prefrontal cortex (DLPFC) of subjects with schizophrenia and that this decrease appears to be associated with a decrease in the expression of the GluR5, but not GluR6, GluR7, KA1 or KA2, subunit of the kainate receptor. In addition, our radioligand binding data did not support the notion that the density of the Nmethyl D-aspartate (NMDA) receptor, measured using two radioligands directed at two discrete sites of the NMDA receptor, or the amino-3-hydroxyl-5-methyl-4-isoxazole (AMPA) receptor is altered in subjects with the disorder.
Turning to the issue of the interpretation of our data on [ 3 H]aspartate binding raised by Balcar and Nanitsos. First of all we must correct the statement made by these authors as we did not, as they suggest, claim that 'glutamate transport in cortical areas affected by schizophrenia is not changed'. In fact, a careful reading of the discussion of our paper reveals that we limited the interpretation of our data to suggesting 'there is no change in the levels of highaffinity glutamate uptake sites in the DLPFC with schizophrenia'. The term 'high-affinity glutamate uptake sites' was used to define sites in the human cortex that bind [ 3 H]aspartate with high affinity and show pharmacological characteristics of a glutamate uptake site (Cross et al, 1986) . In the absence of more defining data, such as the measurement of transcripts for the different glutamate transporters, our binding data could not be interpreted further. Thus, from our perspective, Balcar and Nanitsos have overinterpreted both the molecular and the anatomical extent (we did not make a statement on the entire human cortex) of our comments on [ (Ohnuma et al, 1998) , striatum (McCullumsmith and Meador-Woodruff 2002) , thalamus (Smith et al, 2001a) , and hippocampal formation (Ohnuma et al, 2000) , from subjects with schizophrenia. Moreover, aberrations in glutamatergic function may also result from changes in glutamate uptake by glia (Glt-1 transporter) (Matute et al, 2005) or because of changes in vesicular glutamate transporter (Eastwood and Harrison, 2005; Smith et al, 2001b) in different CNS regions from subjects with schizophrenia. On addressing the issue of changes in glutamate uptake by glia, Balcar and Nanitsos suggest that increased levels of EAATs have been reported in postmortem schizophrenic brains from nonmedicated patients (Matute et al, 2005) . This statement is a little misleading and not carefully defined. The study cited was completed using postmortem CNS from 11 subjects with schizophrenia, 8 of whom were medicated and three of whom 'had not received antipsychotic drugs for an amount of time' before death, only two of which were used for expression studies. The study showed that levels of mRNA for Glt-1 (Glt-1 ¼ EAAT2) were increased in the medicationfree subjects, not changed in tissue from subjects on atypical antipsychotic drugs at death (n ¼ 3), and decreased in subjects on typical antipsychotic drugs at death (n ¼ 5). What conclusions can be drawn from a study where cohorts for analyses consisted of five subjects or less is open to conjecture; however, the study does suggest that antipsychotic drug treatment may be a confounding factor in interpreting results on glutamate transporters in schizophrenia.
Given extensive data from the study of postmortem CNS from subjects with schizophrenia, we would not dispute the suggestion of Balcar and Nanitsos that it is premature to suggest that glutamate transport is not changed in the cortex of subjects with schizophrenia. Indeed, this is why we did not draw that conclusion in our study of glutamatergic markers in the cortex of subjects with the disorder (Scarr et al, 2005) . However, we would suggest debate on a minor component of our study does not in any way detract from our data showing a decrease in the expression of the GluR5 subunit and decreased levels of [
